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1. Introduction 
1.1 Background information 
Biometrics is the science and technology of measuring and analyzing biological data. It also 
refers to technologies that measures and analyzes human body characteristics for 
identification purposes. In the context of this book chapter, identification will refer to the 
recognition of those individuals in a disease state i.e., carcinoma of the breast. Using “start-
of-the-art” mass spectrometry protein analysis, the author will demonstrate the use of 
salivary protein profiles to recognize individuals at risk for carcinoma of the breast. 
Proteomic analyses of varying body fluids are propelling the field of medical research 
forward at unprecedented rates due to its consistent ability to identify proteins that are at 
the fentomole level in concentration. These advancements have also benefited biometric 
research to the point where saliva is currently recognized as an excellent diagnostic medium 
for biometric authentication of human body characteristics. The saliva microbiome, for 
example, is reputed to be biometrically as accurate as a fingerprint. Collectively, these 
efforts are in the area of biological verification; however, biometric can be applied to identify 
the biological characteristics of a diseased individual. 
1.2 Why Saliva as a diagnostic media? 
1.2.1 Analytical advantages of Saliva 
Saliva as a diagnostic fluid has significant biochemical and logistical advantages when 
compared to blood. Bio-chemically, saliva is a clear liquid with an average protein 
concentration of 1.5 to 2.0 mg/ml. As a consequence of this low protein concentration, it was 
once assumed that this was a major drawback for using saliva as a diagnostic fluid; 
however, current ultra sensitive analyte detection techniques have eliminated this barrier. 
Saliva specimen preparation is simple involving centrifugation prior to storage and the 
addition of a cocktail of protease inhibitors to reduce protein degradation for long-term 
storage.  
Blood is a far more complex medium. A decision has to be made as to whether to use serum 
or plasma. Serum has a total protein concentration of approximately 60-80 mg/ml. Since 
serum possesses more proteins than saliva, assaying trace amounts of “factors” (e.g., 
oncogenes, etc.), may result in a greater risk of non-specific interference and a greater chance 
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for hydrostatic (and other) interactions between the factors and the abundant serum 
proteins. Serum also possesses numerous carrier proteins, e.g., albumin, which must either 
be removed or treated prior to being assayed for protein content. Additionally, it has been 
demonstrated that clotting removes many background proteins, which may be altered in the 
presence of disease. It has been demonstrated that enzymatic activity continues during this 
process, which may cleave proteins from many relevant pathways (Koomen et al., 2005).  
It would be ideal if all enzymatic activity in serum would cease at the time of collection; 
however, proteomic analyses of serum has shown that this is not the case. As a consequence, 
plasma is also being explored as a diagnostic fluid. The main consideration in using plasma 
is the selection of a proper anticoagulant (Koomen et al., 2005; Teisner et al., 1983). Heparin 
for example can be used as an anti-clotting agent; however, current research has found that 
heparin has a relatively short half life (3 to 4 hours) and can produce products of 
coagulation which are abundantly comparable to those assayed in serum. Based on these 
observations, it is recommended that blood specimens be collected with ethylenediamine 
tetraacetic acid (EDTA).  
1.2.2 Collection advantages of Saliva 
From a logistical perspective, the collection of saliva is safe (e.g., no needle punctures), non-
invasive and relatively simple, and may be collected repeatedly without discomfort to the 
patient [4]. Consequently it may be possible to develop a simplified method for “home-
testing”, testing in a “health fair” setting or in dental clinics where individuals are available 
for periodic oral examinations. This diagnostic potential could reach many individuals who 
for personal, logistical or economical reasons lack access to preventive care.  
Blood is a more complicated medium to collect. It requires highly trained personnel to 
collect it and if collected incorrectly, can lead to misinterpretations which can result in 
patient mismanagement (Ernest & Balance, 2006). Blood specimens need to be collected in a 
specific sequence and under-filling tubes with additives may possibly alter protein analyses. 
Additionally, if specimens are collected during hospital or clinical settings, there may be a 
lapse of time before being processed.  
1.2.3 Saliva collection 
The oral cavity receives secretions from three pairs of major salivary glands and numerous 
minor salivary glands that are located on the oral buccal mucosa, palate, and tongue each 
producing a unique type of secretion with varying protein constituents (Birkhed & Heintze, 
1989). For example the parotid and Von Ebner glands (located on the tongue) produce 
serous secretions while the minor salivary glands produce mucinous secretions. The 
submandibular and sublingual glands, however, produce mixed secretions which are both 
serous and mucinous. As a consequence, composite or “whole” saliva is preferred as it 
enhances the chances of finding a biomarker due to the variety of sources from which it 
derives and because of its simplicity to collect. 
There are basically two types of saliva to collect. One type is “resting” or unstimulated 
whole saliva and the other is stimulated whole saliva. There are several methods for 
collecting unstimulated whole saliva. These include the draining or drool method, spitting 
method, suction method and the swab method. These methods will yield 0.47, 0.47, 0.54 and 
0.52 ml/minute of saliva respectively. Of the four methods, the most reliable is the suction 
method with a reliability coefficient of r = 0.93. It also revealed a within subject variance of 
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0.14. This is a very reliable method; however, a vacuum pump is required to collect the 
specimens (Birkhed & Heintze, 1989).  
There are several drawbacks when using unstimulated saliva. The major problem is the 
small amount of saliva derived from collection. The 0.47-0.54 ml/minute is the range for 
healthy individuals (0.25–0.35 ml/minute normal range) under ideal conditions using those 
aforementioned collection methodologies. If the subject is taking medications that decrease 
flow rates (e.g., anti-hypertensive medications) the amount collected will be significantly 
reduced. Additionally, if the subject has autoimmune disorders (e.g., Sjögren’s syndrome), 
has under gone head and neck radiation, or is very elderly, it will be difficult to obtain 0.5 
ml over a five minute period. Unstimulated saliva flow rates are also influenced by 
circadian and circannual rhythms. Therefore, for consistency, individuals will need to be 
serially assessed at approximately the same time of day that the baseline specimen was 
collected. All other participants will need to be collected at approximately the same time in 
order to reduce inter-variability among the participating subjects. In conclusion, due to the 
small quantity of specimen obtained from these techniques and the large within subject 
variance, one can conclude that using unstimulated saliva is not the ideal medium for cancer 
biomarker discover. 
The alternative to using unstimulated whole saliva is obviously to use stimulated whole 
saliva. Stimulated secretions produce about three times the volume of unstimulated 
secretions and are not subjected to the effects of circadian rhythm. Additionally, you will be 
able to collect sufficient quantities of saliva despite health status and medication usage. The 
flow rate range is 1 – 3 ml/minute for healthy individuals (Birkhed & Heintze, 1989; Gu et 
al., 2004).  
There are two methods for collecting stimulated whole saliva. One method of collection is 
the gustatory method and the other is the reflexive or “masticatory” technique. The 
gustatory technique requires the use of an oral based secretory stimulant. Citric acid is the 
most widely used stimulant. Five drops of a 1-6% citric acid solution is applied to the 
dorsum of the tongue every 30 seconds. The saliva accumulates in the mouth and is 
expectorated intermittently for a period of five minutes. This technique produces copious 
amounts of saliva; however, the reliability is only r = 0.76 and has a within subject variance 
of 0.49. 
The reflexive method is based on the reflex response occurring during the mastication of a 
bolus of food. Usually, a standardized bolus (1 gram) of paraffin or a gum base (Wrigley 
Co., Peoria, IL) is given to the test subject and they chew the substance at a regular rate. The 
subject expectorates intermittently during the collection period for duration of five minutes. 
This is an accurate technique as it has a reliability coefficient of r = 0.95 and a within subject 
variability of 0.11. The authors recommend this salivary collection method for biomarker 
discovery. 
The procedure for collecting Stimulated Whole Salivary Gland Secretions is as follows: A 
standard piece of unflavored gum base (1.0 - 1.5 g.) is placed in the subject's mouth. The 
armamentarium used for this procedure is illustrated in Figure 1. The patient is asked to 
swallow any accumulated saliva and then instructed to chew the gum at a regular rate 
(using a metronome). The subject, upon sufficient accumulation of saliva in the oral cavity, 
expectorates periodically into a preweighed disposable plastic cup. This procedure is 
continued for a period of five minutes. The cup with the saliva specimen is reweighed and 
the flow rate determined gravimetrically. The volume and flow rate is then recorded along 
with a brief description of the specimen’s physical appearance (Gu et al., 2004).  
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1.2.4. Long-term Saliva specimen banking 
Roughly 2 - 5 ml of whole saliva will be obtained from the individual. In order to minimize 
the degradation of the proteins, protease inhibitor cocktail (Sigma, 1 mg/ml whole saliva) 
and 1 mM of sodium orthovanadate are added immediately after sample collection 
(Shevchenko et al., 2002). All samples are kept on ice during the process. The specimen is 
next divided into 0.5 ml aliquots, placed into bar code labeled cryotubes, and frozen (-80°C).  
To assess specimen degradation, ten healthy subjects were serially sampled for saliva over a 
five-year period. We used c-erbB-2 to test for specimen stability as this is a large 185-kDa 
protein, which would be susceptible to degradation by proteases and other biochemical 
activity. The results are shown in Figure 1 and illustrate protein stability when frozen at -
80°C.These results are consistent with Wu et al, 1993 where they assayed serially sampled 
salivary specimens which were collected over a ten year period for total protein, lactoferrin 
(77 kDa) and histidine rich proteins concentrations. In their study, they found no 
concentration differences due to specimen aging. 
 
 
Fig. 1. Armamentarium for the collection and storage of stimulated whole saliva 
1.3 Studies using Saliva protein profiling for disease state detection 
The majority of the literature concerning human saliva biometrics is associated with the oral 
cavity and its associated maladies. An example of this statement is demonstrated in a 
manuscript assessing salivary proteins associated with burning mouth syndrome (Moura et 
al., 2007). The principle objective the present study was to analyze the characteristics of 
salivary production and its composition in individuals with burning mouth syndrome. The 
investigators compared salivary flow rates, potassium, iron, chloride, thiocyanate, 
magnesium, calcium, phosphorus, glucose, total protein and urea concentrations, as well as 
the expression profile of salivary proteins by SDS-PAGE among healthy individuals and 
those diagnosed with burning mouth syndrome. The results of the study showed that mean 
salivary flow rates among control patients were lower than that of burning mouth syndrome 
patients. Chloride, phosphorus and potassium levels were elevated in patients with burning 
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mouth syndrome (p = 0.041, 0.001 and 0.034, respectively). Total salivary protein 
concentrations were reduced in individuals with burning mouth syndrome (p = 0.223). 
Additionally, the analysis of the expression of salivary proteins by Coomassie blue SDS-
PAGE revealed a lower expression of low molecular weight proteins in individuals with 
burning mouth syndrome compared to healthy controls. The results suggested that the 
identification and characterization of low molecular weight salivary proteins in burning 
mouth syndrome may be important in understanding BMS pathogenesis, thus contributing 
to its diagnosis and treatment. 
Another study using salivary protein profiles investigated the modification of the salivary 
proteome occurring in type 1 diabetes and to highlight potential biomarkers of the disorder. 
High-resolution two-dimensional gel electrophoresis and matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry was combined to perform a large 
scale analysis of the salivary specimens. The proteomic comparison of saliva samples from 
healthy subjects and poorly controlled type-1 diabetes patients revealed a modulation of 23 
proteins. Fourteen isoforms of α-amylase, one prolactin inducible protein, three isoforms of 
salivary acidic protein-1, and three isoforms of salivary cystatins SA-1 were detected as 
under expressed proteins, whereas two isoforms of serotransferrin were over expressed 
secondary to type-1 diabetes. The proteins under expressed were all known to be implicated 
in the oral anti-inflammatory process, suggesting that the pathology induced a decrease of 
non-immunological defense of oral cavity. As only particular isoforms of proteins were 
modulated, type-1 diabetes seemed to differentially affect posttranslational modification of 
the proteins (Hirtz et al., 2006). 
An additional study (Delaleu et al., 2008) investigated the involvement of 87 proteins 
measured in serum and 75 proteins analyzed in saliva in spontaneous experimental 
Sjögren's syndrome. In addition, they intended to compute a model of the immunological 
situation representing the overt disease stage of Sjögren's syndrome. In this animal study, 
they used non-diabetic, non-obese diabetic mice for salivary gland dysfunction. The mice 
aged 21 weeks and were evaluated for salivary gland function, salivary gland inflammation 
and extra-glandular disease manifestations. The analytes, comprising chemokines, 
cytokines, growth factors, autoantibodies and other biomarkers, were quantified using 
multi-analyte profile technology and fluorescence-activated cell sorting. Age-matched and 
sex-matched Balb/c mice served as a reference. The investigators found non-diabetic, non-
obese diabetic mice tended to exhibit impaired salivary flow, glandular inflammation and 
increased secretory SSB (anti-La) levels. Thirty-eight biomarkers in serum and 34 in saliva 
obtained from non-diabetic, non-obese diabetic mice were significantly different from those 
in Balb/c mice. Eighteen biomarkers in serum and three chemokines measured in saliva 
could predict strain membership with 80% to 100% accuracy. Factor analyses identified 
principal components mostly correlating with one clinical aspect of Sjögren's syndrome and 
having distinct associations with components extracted from other families of proteins. They 
concluded that the autoimmune manifestations of Sjögren's syndrome are greatly 
independent and associated with various immunological processes; however, CD40, CD40 
ligand, IL-18, granulocyte chemotactic protein-2 and anti-muscarinic M3 receptor IgG3 may 
connect the different aspects of Sjögren's syndrome. Processes related to the adaptive 
immune system appear to promote Sjögren's syndrome with a strong involvement of T-
helper-2 related proteins in hyposalivation. This approach further established saliva as an 
attractive biofluid for biomarker analyses in Sjögren's syndrome and provides a basis for the 
comparison and selection of potential drug targets and diagnostic markers (Delaleu et al., 
2008). 
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2. Current research in Salivary protein profiling for cancer detection 
2.1 Methods 
2.1.1 Study design 
The purpose of this study was to determine if individuals could be protein profiled and 
potentially classified as having cancer. The investigator also wanted to ascertain if there 
were alterations of the protein profiles due to the primary tissue site and the varying degree 
of tumor staging. In order to achieve this objective, the investigators collected saliva from 
women that were healthy and from those diagnosed with carcinoma breast in the following 
stages: Stage 0, Stage I, Stage IIa and Stage IIb. All the tumors were adenocarcinomas.  
Additionally, specimens were collected from women diagnosed with varying gynecological 
carcinomas. These included women diagnosed with moderate cervical dysplasia, severe 
cervical dysplasia and cervical carcinoma in situ. These tumors were all squamous cell 
carcinomas. Women diagnosed with ovarian and endometrial carcinomas were also 
included in the study. These malignancies were identified as adenocarcinomas. The final 
group consisted of women diagnosed with head and neck squamous cell carcinomas ten 
women with varying stages of development. Due to the difficulty in obtaining early stage 
tumors for ovarian, endometrial and head/neck carcinomas, a composite of varying staged 
patients formed these saliva pools. 
This study was performed under the UTHSC IRB approved protocol number HSC-DB-05-
0394. All procedures were in accordance with the ethical standards of the UTHSC IRB and 
with the Helsinki Declaration of 1975, as revised in 1983. The specimens were banked at the 
University of Texas Dental Branch Saliva repository, which stores the specimens at -80°C. 
Ten saliva specimens were pooled for each type of carcinoma. The saliva samples were 
pooled by combining equal volumes of cleared stimulated whole saliva from a set of 
archived healthy and cancer subjects. The subjects were matched for age and race and were 
non-tobacco users. Previous studies by the investigator have demonstrated that properly 
prepared specimens can remain in storage for a long period of time. 
2.1.2 Saliva collection and sample preparation 
Stimulated whole salivary gland secretion is based on the reflex response occurring during 
the mastication of a bolus of food. Usually, a standardized bolus (1 gram) of paraffin or a 
gum base (generously provided by the Wrigley Co., Peoria, IL) is given to the subject to 
chew at a regular rate. The individual, upon sufficient accumulation of saliva in the oral 
cavity, expectorates periodically into a preweighed disposable plastic cup. This procedure is 
continued for a period of five minutes. The volume and flow rate is then recorded along 
with a brief description of the specimen’s physical appearance (Navazesh &Christensen, 
1982). The cup with the saliva specimen is reweighed and the flow rate determined 
gravimetrically. The authors recommend this salivary collection method with the following 
modifications for consistent protein analyses. A protease inhibitor from Sigma Co (St. Louis, 
MI, USA) is added along with enough orthovanadate from a 100mM stock solution to bring 
its concentration to 1mM. The treated samples were centrifuged for 10 minutes at top speed 
in a table top centrifuge. The supernatant was divided into 1 ml aliquots and frozen at -80°C.  
2.1.3 LC-MS/MS mass spectroscopy with isotopic labeling 
Recent advances in mass spectrometry, liquid chromatography, analytical software and 
bioinformatics have enabled the researchers to analyze complex peptide mixtures with the 
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ability to detect proteins differing in abundance by over 8 orders of magnitude (Wilmarth et 
al., 2004). One current method is isotopic labeling coupled with liquid chromatography 
tandem mass spectrometry (IL-LC-MS/MS) to characterize the salivary proteome (Gu et al., 
2004). The main approach for discovery is a mass spectroscopy based method that uses 
isotope coding of complex protein mixtures such as tissue extracts, blood, urine or saliva to 
identify differentially expressed proteins (18). The approach readily identifies changes in the 
level of expression, thus permitting the analysis of putative regulatory pathways providing 
information regarding the pathological disturbances in addition to potential biomarkers of 
disease. The analysis was performed on a tandem QqTOF QStar XL mass spectrometer 
(Applied Biosystems, Foster City, CA, USA) equipped with a LC Packings (Sunnyvale, CA, 
USA) HPLC for capillary chromatography. The HPLC is coupled to the mass spectrometer 
by a nanospray ESI head (Protana, Odense, Denmark) for maximal sensitivity (Shevchenko 
et al., 2002).  The advantage of tandem mass spectrometry combined with LC is enhanced 
sensitivity and the peptide separations afforded by chromatography. Thus even in complex 
protein mixtures MS/MS data can be used to sequence and identify peptides by sequence 
analysis with a high degree of confidence (Birkhed et al., 1989; Gu et al., 2004; Shevchenko et 
al., 2002; Wilmarth et al., 2004).  
Isotopic labeling of protein mixtures has proven to be a useful technique for the analysis of 
relative expression levels of proteins in complex protein mixtures such as plasma, saliva 
urine or cell extracts. There are numerous methods that are based on isotopically labeled 
protein modifying reagents to label or tag proteins to determine relative or absolute 
concentrations in complex mixtures. The higher resolution offered by the tandem Qq-TOF 
mass spectrometer is ideally suited to isotopically labeled applications (Gu et al., 2004; 
Koomen et al 2004; Ward et al., 1990).  
Applied Biosystems recently introduced iTRAQ reagents (Gu et al., 2004; Koomen et al 2004; 
Ward et al., 1990), which are amino reactive compounds that are used to label peptides in a 
total protein digest of a fluid such as saliva. The real advantage is that the tag remains intact 
through TOF-MS analysis; however, it is revealed during collision induced dissociation by 
MSMS analysis. Thus in the MSMS spectrum for each peptide there is a fingerprint 
indicating the amount of that peptide from each of the different protein pools. Since 
virtually all of the peptides in a mixture are labeled by the reaction, numerous proteins in 
complex mixtures are identified and can be compared for their relative concentrations in 
each mixture. Thus even in complex mixtures there is a high degree of confidence in the 
identification.  
2.1.4 Salivary protein analyses with iTRAQ 
Briefly, the saliva samples were thawed and immediately centrifuged to remove insoluble 
materials. The supernatant was assayed for protein using the Bio-Rad protein assay 
(Hercules, CA, USA) and an aliquot containing 100 µg of each specimen was precipitated 
with 6 volumes of -20ºC acetone. The precipitate was resuspended and treated according to 
the manufacturers instructions. Protein digestion and reaction with iTRAQ labels was 
carried out as previously described and according to the manufacturer’s instructions 
(Applied Biosystems, Foster City, CA). Briefly, the acetone precipitable protein was 
centrifuged in a table top centrifuge at 15,000 x g for 20 minutes. The acetone supernatant 
was removed and the pellet resuspended in 20 ųl dissolution buffer. The soluble fraction 
was denatured and disulfides reduced by incubation in the presence of 0.1% SDS and 5 mM 
TCEP (tris-(2-carboxyethyl)phosphine)) at 60ºC for one hour. Cysteine residues were 
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blocked by incubation at room temperature for 10 minutes with MMTS (methyl methane-
thiosulfonate). Trypsin was added to the mixture to a protein:trypsin ratio of 10:1. The 
mixture was incubated overnight at 37ºC.  
The protein digests were labeled by mixing with the appropriate iTRAQ reagent and 
incubating at room temperature for one hour. On completion of the labeling reaction, the 
four separate iTRAQ reaction mixtures were combined. Since there are a number of 
components that can interfere with the LC-MS/MS analysis, the labeled peptides are 
partially purified by a combination of strong cation exchange followed by reverse phase 
chromatography on preparative columns. The combined peptide mixture is diluted 10 fold 
with loading buffer (10 mM KH2PO4 in 25% acetonitrile at pH 3.0) and applied by syringe to 
an ICAT Cartridge-Cation Exchange column (Applied Biosystems, Foster City, CA) column 
that has been equilibrated with the same buffer. The column is washed with 1 ml loading 
buffer to remove contaminants.  
To improve the resolution of peptides during LCMSMS analysis, the peptide mixture is 
partially purified by elution from the cation exchange column in 3 fractions. Stepwise 
elution from the column is achieved with sequential 0.5 ml aliquots of 10 mM KH2PO4 at 
pH 3.0 in 25% acetonitrile containing 116 mM, 233 mM and 350 mM KCl respectively. The 
fractions are evaporated by Speed Vacuum to about 30% of their volume to remove the 
acetonitrile and then slowly applied to an Opti-Lynx Trap C18 100 ul reverse phase column 
(Alltech, Deerfield, IL) with a syringe. The column was washed with 1 ml of 2% acetonitrile 
in 0.1% formic acid and eluted in one fraction with 0.3 ml of 30% acetonitrile in 0.1% formic 
acid. The fractions were dried by lyophilization and resuspended in 10 ul 0.1% formic acid 
in 20% acetonitrile. Each of the three fractions was analyzed by reverse phase LCMSMS. The 
analytical strategy is illustrated in Figure 2. 
 
 
Fig. 2. Analytical strategy for quantifying peptides using iTRAQ tagging 
www.intechopen.com
The Use of Saliva Protein Profiling as a Biometric Tool  
to Determine the Presence of Carcinoma among Women 
 
257 
2.1.5 Reverse phase LCMSMS 
The desalted and concentrated peptide mixtures were quantified and identified by nano-LC-
MS/MS on an API QSTAR XL mass spectrometer (ABS Sciex Instruments) operating in 
positive ion mode. The chromatographic system consists of an UltiMate nano-HPLC and 
FAMOS auto-sampler (Dionex LC Packings).  Peptides were loaded on a 75cm x 10 cm, 3cm 
fused silica C18 capillary column, followed by mobile phase elution: buffer (A) 0.1% formic 
acid in 2% acetonitrile/98% Milli-Q water and buffer (B): 0.1% formic acid in 98% 
acetonitrile/2% Milli-Q water.  The peptides were eluted from 2% buffer B to 30% buffer B 
over 180 minutes at a flow rate 220 nL/min. The LC eluent was directed to a NanoES source 
for ESI/MS/MS analysis.  Using information-dependent acquisition, peptides were selected 
for collision induced dissociation (CID) by alternating between an MS (1 sec) survey scan 
and MS/MS (3 sec) scans. The mass spectrometer automatically chooses the top two ions for 
fragmentation with a 60 second dynamic exclusion time.  The IDA collision energy 
parameters were optimized based upon the charge state and mass value of the precursor 
ions. Each saliva sample set there are three separate LCMSMS analyses. 
The accumulated MSMS spectra are analyzed by ProQuant and ProGroup software 
packages (Applied Biosystems) using the SwissProt database for protein identification. The 
ProQuant analysis was carried out with a 75% confidence cutoff with a mass deviation of 
0.15 Da for the precursor and 0.1 Da for the fragment ions. The ProGroup reports were 
generated with a 95% confidence level for protein identification.  
2.1.6 Bioinformatics 
The Swiss-Prot database was employed for protein identification while the PathwayStudio® 
bioinformatics software package was used to determine Venn diagrams were also 
constructed using the NIH software program (http://ncrr.pnl.gov). Graphic comparisons 
with log conversions and error bars for protein expression were produced using the 
ProQuant® software. 
2.1.7 Western blot analysis for marker validation  
2.1.7.1 Preparation of samples 
We selected the protein profilin-1 for validating the presence of these proteins in saliva. The 
profilin-1 antibody was a rabbit polyclonal from the Abcam Co. #Ab10608 diluted 1:1000. 
The saliva samples from a healthy individuals, benign tumor subjects and individuals 
diagnosed with Stage IIa her2/neu receptor positive breast cancer subjects and Stage IIa 
her2/neu receptor negative breast cancer subjects were pooled by combining equal volumes 
of cleared stimulated whole saliva from a set of archived specimens. 
The pooled saliva was mixed with loading buffer (Laemmli buffer containing BME) in 1:1 
ratio.  The sample was then incubated at 95°C for 5 minutes and was then loaded onto the 4-
15% Tris-HCl polyacrylamide gel. Four-fifteen percent Tris-HCl polyacrylamide gels were 
loaded with molecular weight markers, controls, and the pooled saliva samples.  
Electrophoresis was run at 200 Volts, 30 minutes in 1X TGS buffer. The gels were 
equilibrated and extra thick blot paper and PVDF membranes were soaked in 1X TGS buffer 
for 15 minutes prior to running Western Transfer.  Semi-dry transfer apparatus was used.  
Transfer conditions were 0.52mA constant, 17 volts, 19 minutes. Polyvinylidene fluoride 
(PVDF) membranes were air dried for minimum of 1 hour. Dry PVDF membranes were 
activated in methanol for about 10 seconds then transferred to soak in 1X PBS-T for 3 washes 
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of 5 minutes each. The membranes were then incubated for 1 hour in 5% NFDM in PBS-T. 
Afterwards the membranes were washed 3 times for 5 minutes in PBS-T. The membranes 
were incubated overnight with a primary antibody in PBS-T. The membranes were washed 
3 times for 5 minutes in PBS-T and were incubated for 4 hours with secondary antibody 
(HRP conjugate) in PBS-T. Again, the membranes were washed 3 times for 5 minutes in PBS-
T. Finally, the membranes were treated with ECL plus detection reagents and photographed 
with exposure of 800 seconds. 
3. Experimental results in salivary protein profiling for cancer detection 
3.1 Mass spectrometry analysis 
Tables 1-5 summarize the results of the proteomic analysis and illustrates protein 
comparisons between breast (Stage 0 – IIb), cervical (moderate, severe dysplasia and in situ) 
 
Proteins 
Breast Ovarian Endo. Cervical H & N 
Staging 
Gene ID Accession
Stage
0 
Stage
I 
Stage
IIa 
Stage
IIb 
Variable Variable Mod. Severe Stage 0 Variable 
A1AT P01009                   4.32 
ANXA3 P12429                   0.74 
CO3 P01024                   2.16 
HPTR P00739                   3.57 
K1C16 P08779                 5.37   
COBA1 P12107             0.57       
LUZP1 Q86V48             0.62       
ZN248 Q8NDW4             0.84       
CYTC P01034             0.77       
KAC P01834         1.42           
K2C6C P48666 3.40                 
K1CJ P13645   0.47   0.26       
SCOT2 Q9BYC2     0.83 0.50             
VEGP P31025 1.36   0.47               
PROF1 P07737 0.74                 
NGAL P80188 0.90                 
NUCB2 P80303   1.28               
HEMO P02790 0.74                   
CYTD P28325   0.82                 
CRIS3 P54108 0.65                   
ACBP P07108 1.42                   
KLK P06870 0.80 1.46 0.86               
PIP P12273 0.88 0.80                 
PERL P22079   1.31 0.88               
PPIB P23284   1.32                 
Table 1. The table shows which proteins are unique to each type and stage of carcinoma 
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Protein Status 
Breast Ovarian Endo. Cervical H & N 
Staging 
Stage 0 Stage I Stage IIa Stage IIb Variable Variable Mod. Severe Stage 0 Variable 
Unique Proteins 
Up Regulated 3 4 0 0 1 0 0 0 1 2 
Down Regulated 6 3 4 2 0 0 4 0 0 2 
Total Proteins 9 7 4 2 1 0 4 0 1 4 
Common Proteins 
Up Regulated 16 7 2 7 17 21 20 13 13 15 
Down Regulated 8 11 11 7 5 5 7 4 8 7 
Total Proteins 24 18 13 14 22 26 27 17 21 22 
Total Number Proteins 
Up Regulated 19 11 2 7 18 21 20 13 14 17 
Down Regulated 14 14 15 9 5 5 11 4 8 9 
Grand Total 33 25 17 16 23 26 31 17 22 26 
Table 2. The table demonstrates the unique, common and total protein counts among the 
varying carcinomas and their stages 
ovarian, endometrial and head and neck cancer subjects. The values exhibited in table 1 and 
table 2 represent the ratio of disease state to healthy state. Simply stated the ratio for each 
protein is a result of the log sum integrated area under each peak formed when plotting the 
intensity versus mass-to-charge ratios for each peptide (Boehm et al., 2007). The value is 
divided by the corresponding value yielded for that particular protein in the healthy cohort. 
Significance between ratios is determined by t-test analysis.  Those with values greater than 
1.000 were considered up-regulated proteins while those with values less than 1.000 were 
considered down-regulated proteins.  
In total, 166 proteins were identified at a confidence level at >95. Of these there were 76 
proteins that were determined to be expressed significantly different (p<0.05) in the saliva 
from cancer subjects as compared to the healthy individuals. Table 1 lists the 25 proteins 
that are unique to each type of carcinoma with their corresponding ratios. Unique being 
defined as not associated with the other types of carcinoma. Eleven of the unique proteins 
were up-regulated and fourteen were down-regulated. There were no unique proteins 
associated with endometrial carcinoma or severe dysplasia of the cervix. Carcinoma of the 
breast and its associated stages accounted for nearly 58% of the total unique proteins. 
Table 3 indicates the function of the associated proteins. Generally, the proteins appear to be 
diverse with the exception of the cytoskeletal associated proteins which comprised 20% of 
the protein panel. Additionally, over 50% of the proteins in table 3 are referenced in the 
literature for the presence of carcinoma in blood and cell supernatants from cancer cell lines 
(Polanski & Anderson, 2006). 
The following table represents the up and down-regulated proteins that over-lapped the 
various types of carcinomas. Numerous proteins, 21 percent, were common to both 
squamous cell carcinoma and the adenocarcinoma cancer types. This was particularly 
noticed among the S100 proteins. There were 13 proteins that were exclusive to the 
gynecological carcinomas despite the fact that some were squamous cell carcinoma or 
adenocarcinoma cancer types. These proteins comprised 25% of the protein panel. Table 5 
illustrates the function of the proteins listed in table 4. 
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Gene ID Accession Protein Name Reported Function 
A1AT P01009 Alpha 1 protease inhibitor Protease inhibitor
ACBP P07108 AcylCoA binding protein Transport protein
ANXA3 P12429 Annexin A3 Inhibits phospholipase activity 
CO3 P01024 Complement 3 precursor Activates complement  system 
COBA1 P12107 Collagen alpha-1 chain Fibrillogenesis
CRISP3 P54108 Cysteine rich secretory protein Immune response
CYTC P01034 Cystatin C Inhibitor of cysteine proteases 
CYTD P28325 Cystatin D precursor Protein degradation & inhibitor 
HEMO P02790 Hemopexin precursor Heme transporter protein 
HPTR P00739 Haptoglobin – 1 related protein proteolysis
K1C16 P08779 Cytoskeleton 16 Cytoskeleton associated 
K1CJ P13645 Cytoskeleton 10 Cytoskeleton associated 
K2C6C P48666 Cytoskeleton 6C Cytoskeleton associated  
KAC P01834 Immunoglobulin kappa chain C 
region
Immune response
KLK P06870 Kallikrein-1 Cleaves kininogen
LUZP1 Q86V48 Leucine zipper protein-1 Nucleus functioning protein 
NGAL P80188 Neutrophil Gelatinase associated 
lipocalin
Iron trafficking protein 
NUCB2 P80303 Nucleobindin-2 precursor Calcium binding protein 
PERL P22079 Lactoperoxidase Transport, antimicrobial 
PIP P12273 Prolactin inducible protein precursor Secretory actin binding protein 
PPIB P23284 Peptidyl-prolyl cis trans isomerase B Accelerates protein folding 
PROF1 P07737 Profilin-1 Cytoskeleton associated 
SCOT2 Q9BYC2 Succinyl CoA Ketone body catabolism 
VEGP P31025 Lipocalin - 1 Ligand binding protein 
ZN248 Q8NDW4 Zinc finger protein 248 Transcriptional regulation 
Table 3. The table reveals the protein functions associated with the varying carcinomas and 
their stages 
Proteins 
Breast Ovarian Endo. Cervical H & N 
Staging
 Gene ID Accession
Stage
0
Stage
I
Stage 
IIa
Stage 
IIb
Variable Variable Mod. Severe Stage 0 Variable 
1433S O70456 1.50 2.14 2.09 2.12   
ADA32 Q8TC27 0.52 0.69   
ALBU P02768 0.86 0.91 1.46 1.15 1.23 1.94 2.50 
ALK1 P03973 2.94 1.33   
AMYS P04745 0.84 1.11 0.75 0.84 0.47 0.58 0.55 0.78 0.65 
ANXA1 P04083 1.54 1.43 3.79 2.04 2.06 0.63 
BPIL1 Q8N4F0 1.15 1.94 0.86 1.78 
CAH6 P23280 1.46 0.85 1.57   
CYTA P01040 1.63 1.16   
CYTN P01037 0.77 0.53 1.16 0.67 0.73 
CYTS P01036 0.80 0.64 0.59 
CYTT P09228 1.14 0.59 0.49 0.62 0.50 
DEF3 P59666 3.86 2.61 1.17   
Table 4. Represents the up and down-regulated proteins that over-lapped the various types 
of carcinomas. 
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Proteins 
Breast Ovarian Endo. Cervical H & N 
Staging 
 Gene ID Accession
Stage
0 
Stage
I 
Stage 
IIa 
Stage 
IIb 
Variable Variable Mod. Severe Stage 0 Variable 
DMBT1 Q9UGM3         1.83 1.40 1.22       
ENOA P06733   0.74 0.81     1.71     1.43 1.55 
FABPE Q01469 1.56             0.55     
FGRL1 Q8N441         0.21 0.44 0.64       
HPT P00738 0.65     2.22 1.94       2.64   
IGHA1 P01876         1.23 1.55 1.55 1.23   1.34 
IGHA2 P01877           1.81 1.65     2.18 
IGHG1 P01857 1.26 0.83         1.41   1.48 1.50 
IGHG2 P01859   0.82     0.80       1.58 1.89 
IGJ P01591   1.23       1.41     0.77 1.30 
K1C13 P13646           3.50 6.21 5.91   0.73 
K1C14 P02533         5.34 6.55         
K1CM P13646 3.92       2.95           
K1CP P08779     0.13 0.13 2.61           
K22O Q01546         7.47 5.40         
K2C1 P04264 0.46 0.63 0.33 0.32     2.07 2.22     
K2C4 P19013 4.42       4.47 4.17 5.46 5.91 1.11 0.54 
K2C5 P13647         3.08 5.39 2.65 3.49 0.75   
K2C6A P02538         4.34 5.78         
K2C6E P48668     0.10 0.09           
LAC P01842     0.84     1.43 1.51     1.62 
LCN1 P31025           0.72 1.33       
LV3B P80748         1.33   1.26       
MUC P01871 1.22 0.72             1.45 
MUC5B Q9HC84 1.25 0.71 0.54 1.26 1.39   2.04 1.75   2.15 
PERM P05164   0.72       1.88         
PIGR P01833 0.82               0.88 1.29 
PRDX1 Q06830           1.67 1.22       
S10A7 P31151 2.05       0.67 1.26   0.74 0.76   
S10A8 P05109 1.46 1.36 0.76 1.33   1.49 3.46 3.35 1.42 1.73 
S10A9 P06702   1.53 0.67 1.15   3.86 3.10 1.38 1.73 
SPLC2 Q96DR5 1.22 1.18 0.87 0.68     0.74 1.22 2.11   
SPRR3 Q9UBC9 1.10 0.87   1.42         1.92   
THIO P10599 1.51               1.43   
TRFE P02787 0.80 0.80 0.83           2.00 2.36 
TRFL P02788 1.36 1.19             0.64   
TRY P07477     1.46 1.66     0.84 0.88     
ZA2G P25311 0.90           0.91 1.13 1.29   
 
Table 4. Represents the up and down-regulated proteins that over-lapped the various types 
of carcinomas.(continuation) 
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Gene 
ID 
Accession Protein Name Reported Function 
1433S O70456 1433 sigma Signaling
ADA32 Q8TC27 Disintegrin  Role in sperm development 
ALBU P02768 Albumin Protein transport
ALK1 P03973 Antileukoproteinase Acid-stable proteinase inhibitor 
AMYS P04745 Amylase Enzyme
ANXA1 P04083 Annexin A1 Involved in exocytosis 
BPIL1 Q8N4F0 Bactericidal/permeability-increasing 
protein-like 1 
Lipid binding
CAH6 P23280 Carbonic anhydrase 6 Hydration of carbon dioxide. 
CYTA P01040 Cystatin-A Intracellular thiol proteinase 
inhibitor.
CYTN P01037 Cystatin-SN Cysteine proteinase inhibitors 
CYTS P01036 Cystatin-S Inhibits papain and ficin 
CYTT P09228 Cystatin-SA Thiol protease inhibitor 
DEF3 P59666 Neutrophil defensin 3 Antimicrobial activity 
DMBT1 Q9UGM3 Deleted in malignant brain tumors 1  Candidate tumor suppressor gene  
ENOA P06733 Alpha-enolase Multifunctional enzyme 
FABPE Q01469 Fatty acid-binding protein, 
epidermal 
Keratinocyte differentiation 
FGRL1 Q8N441 Fibroblast growth factor receptor 1 Negative effect on cell proliferation 
HPT P00738 Haptoglobin Combines with free hemoglobin 
IGHA1 P01876 Ig alpha-1 chain C region Immune Response
IGHA2 P01877 Ig alpha-2 chain C region Immune Response
IGHG1 P01857 Ig gamma-1 chain C region Immune Response
IGHG2 P01859 Ig gamma-2 chain C region Immune Response
IGJ P01591 Immunoglobulin J chain Immune Response
K1C13 P13646 Cytokeratin 13 Cytoskeleton
K1C14 P02533 Cytokeratin 14 Cytoskeleton
K1CM P13646 Keratin, type I cytoskeletal 13 Cytoskeleton
K1CP P08779 Keratin, type I cytoskeletal 16 Cytoskeleton
K22O Q01546 Keratin, type II cytoskeletal 2 oral Contributes to terminal 
cornification
K2C1 P04264 Keratin, type II cytoskeletal 1 Regulate the activity of kinases 
K2C4 P19013 Keratin, type II cytoskeletal 4 Cytoskeleton
K2C5 P13647 Keratin, type II cytoskeletal 5 Protein binding
K2C6A P02538 Keratin, type II cytoskeletal 6A Protein binding
K2C6C P48666 Keratin, type II cytoskeletal 6C Structural molecule activity 
K2C6E P48668 Keratin, type II cytoskeletal 6C Cytoskeleton organization 
LAC P01842 Lactoperoxidase Antimicrobial
LCN1 P31025 Lipocalin-1 precursor Plays a role in taste reception. 
LV3B P80748 Ig lambda chain V-III region LOI Activates complement pathway  
MUC P01871 Ig Mu Chain Immune Response
MUC5B Q9HC84 Mucin-5B Contribute to the lubricating  
PERM P05164 Myeloperoxidase Microbiocidal activity
PIGR P01833 Polymeric immunoglobulin receptor Binds IgA and IgM at cell surface 
PRDX1 Q06830 Peroxiredoxin-1 Involved in redox regulation  
Table 5. The table represents the function of the common proteins associated with the 
various types of carcinomas. 
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Gene 
ID 
Accession Protein Name Reported Function 
S10A7 P31151 S100 A7 Interacts with RANBP9 
S10A8 P05109 S100 A8 Calcium-binding protein 
S10A9 P06702 S100 A9 Calcium-binding protein 
SPLC2 Q96DR5 Epithelial carcinoma associated 
protein-2
Lipid binding protein
SPRR3 Q9UBC9 Small proline-rich protein 3 Protein of keratinocytes. 
THIO P10599 Thioredoxin Redox activity
TRFE P02787 Serotransferrin Iron binding transport proteins 
TRFL P02788 Lactotransferrin precursor Iron binding transport proteins 
TRY P07477 Trypsin-1 Activity against synthetic substrates  
ZA2G P25311 Zinc alpha-2 glycoprotein Signaling
Table 5. The table represents the function of the common proteins associated with the 
various types of carcinomas.(continuation) 
3.2  Western blot analyses 
The results of the western blot suggest the presence of profilin-1 in saliva. Figure 3 
illustrates the presence of profilin-1 protein in both the human submandibular gland cell 
lysates and in whole saliva.  
 
 
Fig. 3. The western blot indicates the presence of the 15 kDa profilin-1 protein in human 
submandibular gland cell lysates and stimulated whole saliva 
The western blot analyses also revealed the presence of profilin-1 In SKBR3 cell lysates.  
 
 
Fig. 4. Also revealed the presence of profilin-1 In SKBR3 HER2/neu receptor positive breast 
cancer cell lysates.  
Figure 4
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Figure 5 illustrates the presence of profilin-1 in the saliva sampled from healthy, benign and 
malignant tumor patients. Profilin is a down-regulated protein in the presence of 
malignancy and it is visualized by the lighter bands associated with malignancy. It is also 
worth noting that the Her2/neu receptor negative band is darker than the Her2/neu 
receptor positive counterpart suggesting further down-regulation of the profilin-1 protein. 
 
 
Fig. 5. This figure illustrates the presence and modulation of salivary profilin-1 protein 
secondary to HER2/neu receptor status. 
3.3 Conclusions 
It is interesting to note that the salivary protein profile mimics the findings of protein 
alterations secondary to cancer in serum, tissues and cell lysates that are numerously cited 
in the literature (Polanski et al, 2006). For example, there are salivary protein alterations in 
the cytoskeleton phenotype, which are strongly implicated in tumor growth and cancer 
metastases. Additionally, there are alterations in the metabolic, growth and signaling 
pathways all of which provide support for the concept that salivary protein profiles are 
altered secondary to the presence of cancer. 
The investigator has spent 15 years investigating the phenomena and postulates, that in the 
presence of disease, i.d., carcinoma, that there is an over abundance of protein resulting from 
the rapid growth of the malignancy which in turn, produces a humoral response in the 
salivary glands. This response results in altered salivary protein concentrations. Another 
possible explanation is active transport of the proteins of interest. It is plausible that these 
proteins are secreted into saliva as consequence of localized regulatory function in the oral 
cavity via signal transduction similar to the proposed explanation of HER-2/neu protein in 
nipple aspirates. These “loop” mechanisms, in health, appear to be in equilibrium both 
intercellularly and extracellularly with each pathway fulfilling the resultant phenotypic 
process of growth, proliferation, and differentiation. 
Figure 5
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The results of this preliminary study suggest that there are two panels of biomarkers that 
need to be assessed. There are those biomarkers that are unique to each tumor site i.e., 
breast, cervix, etc. and those that are common to various types of malignancies. The finding 
may prove to be useful. It may be possible to develop a “global” profile for the overall 
detection of cancer while using the unique protein identifiers to determine the site of the 
tumor. Theoretically, by using the biomarkers S100A7, S100A8 and S100A9 you may predict 
the presence of a malignancy and by using the biomarkers listed in table 1 you, potentially 
could determine the site of the tumor. This is merely speculation at this time; however, 
advances in mass spectrometry and microarray technology may make the concept cost 
effective and logistically feasible.   
These results are very preliminary and investigated only the abundant proteins found in 
saliva. Further research is required to determine the low abundant protein profiles 
associated with the various carcinomas. Additionally, the peptidome and the fragmetome 
need to be evaluated to further enhance the profile.  Other carcinomas such as lung, colon, 
pancreas, bladder, skin, brain and kidney at varying stages of development also need to be 
studied and their resultant profiles added to the catalogue of cancer associated protein 
profiles. One major question that is essential to answer is, “Are we identifying the primary 
site of the tumor’s origin?” This information is essential for rendering “tailored” treatment 
regimens. 
The results of this study suggest that it is feasible to employ biometric principles for cancer 
detection. It is obvious from the resultant data that cancer is a very complex disease process 
involving numerous gene alterations in varying numbers of molecular pathways. This in 
turn renders the concept of the single biomarker as passé with respect to cancer detection. 
The multi-marker approach is evident as it avoids the pitfalls of a single marker concept as 
demonstrated by the current shortcomings of the prostate specific antigen marker for 
prostate cancer. Due to the overwhelming complexity of the malady high-throughput 
protein detection coupled with protein modeling in health and disease may yield the tools 
necessary for life saving early cancer detection. 
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